RxDoctor Payments Data

Eric Tallent, MD

Obstetrics · Huntsville, ALNPI 1801883715

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 9 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $84 and has fallen 71.8% since, to $24 in 2025.

$237in general payments, 2019–2025

Across 13 payments — averaging $18.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$48
  • Hologic Sales And Service, LLC$37
  • Therapeuticsmd, Inc.$36
  • Kowa Pharmaceuticals America, Inc.$33
  • Mayne Pharma Commercial LLC$29
  • Daiichi Sankyo Inc.$16
  • plus $38 from 3 others

What the payments were for

  • Food & beverage$237100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few obstetrics providers in Alabamato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$6,095
Medicare patients
40
Services billed
81

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PremarinEstrogens, Conjugated21$11,147
Estradiol98$5,584
CombipatchEstradiol/Norethindrone Acet13$3,060
ValacyclovirValacyclovir Hcl31$1,284
Betamethasone Valerate19$366
Medroxyprogesterone Acetate21$362
Fluconazole12$168
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip14$104
Alprazolam24$81
Diazepam22$61
Promethazine Hcl11$42

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin$48$11,14721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few obstetrics providers in Alabamaon file to place this against a meaningful peer group, so we don't.

Other obstetrics in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →